News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Omnia Korani: Pembrolizumab plus chemotherapy did not improve DFS in high-risk endometrial cancer
Omnia Korani/LinkedIn
Oct 20, 2024, 17:10

Omnia Korani: Pembrolizumab plus chemotherapy did not improve DFS in high-risk endometrial cancer

Omnia Korani, Assistant Lecturer at the National Cancer Institute, shared a post on LinkedIn:

“Adjuvant pembrolizumab plus chemotherapy did not improve DFS in patients with newly diagnosed, high-risk, all-comer endometrial cancer. Preplanned subgroup analyses for stratification factors suggest that pembrolizumab plus chemotherapy improved DFS in patients with dMMR tumours. Safety was manageable.”

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Authors: T. Van Gorp, D. Cibula, W. Lv, F. Backes, F. Ortaç, K. Hasegawa, K. Lindemann, A. Savarese, A. Laenen, Y.M. Kim, L. Bodnar, M.-P. Barretina-Ginesta, L. Gilbert, B. Pothuri, X. Chen, M.B. Flores, T. Levy, N. Colombo, C. Papadimitriou, T. Buchanan, L.C. Hanker, G. Eminowicz, L. Rob, D. Black, J. Lichfield, G. Lin, R. Orlowski, S. Keefe, A. Lortholary, B. Slomovitz on behalf of the ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators.

Omnia Korani: Pembrolizumab plus chemotherapy did not improve DFS in high-risk endometrial cancer

Source: Omnia Korani/LinkedIn

Adjuvant pembrolizumab cancer chemotherapy DFS disease-free survival dMMR tumors high-risk endometrial cancer newly diagnosed Omnia Korani OncoDaily Oncology safety subgroup analyses
Special Coverage
Blog
Dec 30, 2024, 19:52
CelloType: A New Machine Learning Tool for Analyzing Cancer Cells and Tissues
Blog
Dec 30, 2024, 19:26
“QI Scholar Nursing Presentations Part 2” from the SIOP Nursing Network
Science
Dec 30, 2024, 13:52
Nico Gagelmann: Selected clinical studies 2024 in hematology
Insight
Dec 30, 2024, 13:43
Roupen Odabashian: When it comes to real-life cases, physicians still outperform AI
Blog
Dec 30, 2024, 13:42
Shaban Juma: The key to being one step ahead in the fight against cancer
Positive
Dec 30, 2024, 13:42
Improving the lives of children with cancer everywhere - St. Jude Children's Research Hospital
Blog
Dec 30, 2024, 13:37
Matthew Pech: The failure of ex vivo gene therapy for sickle cell and the role of the TPP in the drug development process
Insight
Dec 30, 2024, 13:35
James Crowley: Elevated expression of CCR7 is generally indicative of poor prognosis in cancers
Insight
Dec 30, 2024, 13:30
Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer
Blog
Dec 30, 2024, 13:25
Sanjay Popat: Wouldn’t it be great if FDA Oncology approvals were mutually approvable by MHRA?
Insight
Dec 30, 2024, 13:23
Satya Prakash Yadav: 2024 blockbuster Menin inhibitor for infant ALL
Insight
Dec 30, 2024, 13:10
Promising response to lurbinectedin in NUT carcinoma by M.V. Sánchez Becerra et al. - Vivek Subbiah